Q-omics provides the consensus-scored BEST4 profile across patient tissues and cancer cell-line models. BEST4 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, BEST4 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, BEST4 RNA expression shows 18,235 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where BEST4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BEST4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BEST4 survival associations across molecular data types. BEST4 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BEST4 RNA expression–survival associations across cancer types. High BEST4 expression shows unfavorable associations in ACC, LGG and KIRC, but favorable associations in SKCM, COAD and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for BEST4 RNA expression.
This table summarizes BEST4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for BEST4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BEST4 shows lower tumor expression in COAD and KICH and higher tumor expression in KIRC, THCA, HNSC and LIHC. The COAD box plot shows higher BEST4 RNA expression in normal versus tumor tissue (log2 FC = −5.782, t-test p < 0.001).
This table shows molecular features associated with BEST4 in patient tissues and cancer cell lines. In patient samples, BEST4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, BEST4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and CNS.
